HMOX1 and prostate adenocarcinoma: In the case of prostate adenocarcinoma there was 53% of samples HO-1(-)/ANXA2(+), 18.7% HO-1(+)/ANXA2(+), 9.6% HO-1(+)/ANXA2(-), and 18.7% HO-1(-)/ANXA2(-) (Figure 5C).